Cargando…
Quantitative structure–activity relationship modeling for predication of inhibition potencies of imatinib derivatives using SMILES attributes
Chronic myelogenous leukemia (CML) which is resulted from the BCR-ABL tyrosine kinase (TK) chimeric oncoprotein, is a malignant clonal disorder of hematopoietic stem cells. Imatinib is used as an inhibitor of BCR-ABL TK in the treatment of CML patients. The main object of the present manuscript is f...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755126/ https://www.ncbi.nlm.nih.gov/pubmed/36522400 http://dx.doi.org/10.1038/s41598-022-26279-8 |